3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics Read More » February 25, 2025
3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Potential Groundbreaking ADHD Therapy Read More » February 17, 2025
3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling Read More » August 18, 2023
3Z closes $2 million funding for preclinical development of novel ADHD and Insomnia therapeutics identified by 3Z´s zebrafish drug discovery platform Read More » June 20, 2022
